Kecha AQSh FDA Sietl Genetika kompaniyasining antikor-dori konjugati Adcetris (brentuximab vedotin) ilgari davolangan III yoki IV klassik Hodgkin limfomasi (cHL) bilan og'rigan bemorlar uchun kimyoterapiya bilan birgalikda ma'qullanganini e'lon qildi. Ushbu tasdiqlash 40 yildan ko'proq vaqt oldin klinik amaliyotga kiritilgan ilgari Xodkin limfomasini davolashning dastlabki rejasi yaxshilanganligini anglatadi.
Lymphoma is a type of cancer that begins in the lymphatic system. The immune system helps the body fight infections and diseases. Lymphoma can develop almost anywhere in the body and can spread to nearby lymph nodes. It is divided into two types: Xodkin limfomasi and non-Hodgkin lymphoma. Most patients with Hodgkin limfoma belong to the classic type. In this type of lymph node, there are large abnormal lymphocytes (a type of white blood cell). Called Reed-Sternberg cells. Through early intervention, patients with Hodgkin’s lymphoma usually get long-term remission.
Klinik tekshiruvda Adcetrisning klassik Xodkin lenfomasini davolash bo'yicha potentsiali tasdiqlandi - tadqiqotchilar ilgari o'rtacha 1,334 kunlik tsiklning 6 ta kursini olgan 28 davolash qilingan bemorni jalb qilishdi. Keyinchalik, ular ikki guruhga bo'lingan, bir guruh Adcetris va kimyoviy terapiya (AVD), boshqa guruh esa faqat kimyoviy terapiya (ABVD) olgan. Tadqiqotlar shuni ko'rsatdiki, kombinatsiyalangan terapiya bilan shug'ullanadigan bemorlarda kasallikning rivojlanish xavfi, o'lim yoki yangi davolanishni boshlash zarurati faqat kimyoviy terapiya bilan shug'ullanadigan bemorlarga nisbatan 23 foizga pastdir.
Adcetris combines antibodies and drugs, allowing antibodies to direct drugs to limfoma hujayralari called CD30, approved for treatment of relapsed classic Hodgkin lymphoma, classic Hodgkin lymphoma with high risk of relapse or progression after stem cell transplantation, accepted Systemic anaplastic large cell lymphoma that other treatments are not effective, and primary cutaneous anaplastic large cell lymphoma that does not work with other treatments.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
